Browse drugs

…otic and/or immunosuppressive therapy; post-VHD treatments were aspirin (48.6%), anticoagulants (50%), hydroxychloroquine (86.1%), gluc…

…nd plasma exchange was given without efficacy so treatment with obinutuzumab plus cyclophosphamide was initiated, with gradual neurological …

…d APS, refractory to glucocorticoids, successfully treated with ravulizumab, a terminal complement inhibitor.Methods A 30-year-old woman wi…

…nosed with SLE, while one patient developed uveitis while under azathioprine treatment. Therapeutic management included local corticosteroid…

…ximab, and plasmapheresis, followed by maintenance therapy with mycophenolate mofetil and voclosporin, can result in significant renal and pulmonary …

…c, clinical, serological data and treatment histories (steroid, hydroxychloroquine, immunosuppressives) were documented. Comorbid diseases were do…

…ntenance in 69% of cases, a total of 14.5% of patients received rituximab as a rescue therapy, while 20.3% were treated with CYC as a rei…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

…ected. Forty-eight patients received B-cell targeted therapies (belimumab 40=; rituximab n=8). For these, treatment duration, reasons for…

…b in 25, belimumab in 16, obinutuzumab in 2, voclosporin in 21, tacrolimus in 6, cyclosporin-A in 4 and azathioprine in 3 patients. Six pa…

…Objectives Belimumab (BEL) is a B-cell modulating anti-BLyS mAb approved for SLE (20…

…ndings suggest potential renal protective effects through which belimumab may prevent progression to LN.Funding: GSKOriginal presentation…